{"Clinical Trial ID": "NCT00435409", "Intervention": ["INTERVENTION 1:", "- Sunitinib + Capecitabine", "Sunitinib is administered orally at an initial dose of 37.5 mg once daily on a continuous diet. Capecitabine is administered orally at an initial dose of 2000 mg/m^2 per day (1000 mg/m^2 IDB) from days 1 to 14 every 3 weeks.", "INTERVENTION 2:", "- Capecitabine", "At the time of progression, participants could have been admitted to a single sunitinib agent, administered orally at an initial dose of 37.5 mg per day continuously."], "Eligibility": ["Incorporation criteria:", "A locally advanced or metastatic disease that can be measured. Patients with bone disease only are also allowed to enter the study.", "Previous treatment with anthracycline and taxane in any setting", "Progress of first- and second-line treatment or adjuvant treatment if the disease-free interval is less than 12 months", "- Exclusion criteria:", "\u2022 History of inflammatory carcinoma if there is no other measurable disease", "More than 2 chemotherapeutic agents in the advanced setting of the disease", "- Brain metastases"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "\u2022 Defined as the time from the date of randomization to the date of the first documentation of objective tumour progression or death due to any cause, depending on the first possibility. If the tumour progression data include more than one date, the first date will be used. PFS (in months) will be calculated as (first event date minus randomization date plus 1) divided by 30.4.", "Timeline: Baseline to disease progression (up to 3 years after first dose)", "Results 1:", "Title of the arm/group: Sunitinib + Capecitabine", "Sunitinib administered orally at an initial dose of 37.5 mg once daily on a continuous diet Capecitabine administered orally at an initial dose of 2000 mg/m^2 per day (1000 mg/m^2 IDB) from 1-14 days every 3 weeks.", "Total number of participants analysed: 221", "Median (95% confidence interval)", "Unit of measure: month Independent radiology assessment: 5.5 (4.5 to 6.0)", "\u25cf Investigator's assessment: 5.4 (4.4 to 5.8)", "Results 2:", "Title of the arm/group: Capecitabine", "- Arm/group description: Capecitabine administered orally at an initial dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from days 1 to 14 every 3 weeks. At the time of progression, participants could have been eligible for a single sunitinib crossover administered orally at an initial dose of 37.5 mg per day continuously.", "Total number of participants analysed: 221", "Median (95% confidence interval)", "Unit of measure: month Independent radiology assessment: 5.9 (5.4 to 7.6)", "\u25cf Investigator's assessment: 5.5 (4.3 to 6.8)"], "Adverse Events": ["Undesirable Events 1:", "Total: 85/217 (39.17 per cent)", "Anemia * 7/217 (3.23%)", "* 1/217 (0.46%)", "Leukopenia * 2/217 (0.92%)", "Neutropenia * 3/217 (1.38%)", "Thrombocytopenia * 7/217 (3.23%)", "Pancytopenia * 21/217 (0.46%)", "Acute heart failure * 1/217 (0.46%)", "Congestive cardiomyopathy * 0/217 (0.00 %)", "* 1/217 (0.46%)", "Superventricular tachycardia * 0/217 (0.00 %)", "Adverse Events 2:", "Total: 59/215 (27.44%)", "Anemia * 1/215 (0.47%)", "* 0/215 (0.00 %)", "Leucopenia * 0/215 (0.00 %)", "Neutropenia * 0/215 (0.00 %)", "Thrombocytopenia * 0/215 (0.00 %)", "Pancytopenia * 20/215 (0.00 %)", "Acute heart failure * 0/215 (0.00 %)", "Congestive cardiomyopathy * 1/215 (0.47%)", "Pericardial infusion * 0/215 (0.00 %)", "Superventricular tachycardia * 1/215 (0.47%)"]}